Document is current
Any future updates will be listed below
-
Authors
Ezra, Daniel
Collins, Atif
Haskova, Zdenka https://orcid.org/0000-0003-0535-1267
Kuenzel, Thomas
Ida, Hiroaki
Triyatni, Miriam
Brittain, Christopher https://orcid.org/0009-0009-6212-8118
Idowu, Oluwatobi https://orcid.org/0000-0003-3269-5719
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05987423 at ClinicalTrials.govnct06106828 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials
https://doi.org/10.1007/s40123-025-01255-3
Documents that mention this clinical trial
Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials
https://doi.org/10.1007/s40123-025-01255-3
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche
- License Information
-
More Information
Article History
Received: 21 July 2025
Accepted: 19 September 2025
First Online: 9 October 2025
Declarations
:
: Daniel Ezra has no conflicts of interest to declare. Atif Collins reports being an unpaid member of the study review committee. Zdenka Haskova, Christoper Brittain, and Oluwatobi Idowu report employment by and stock/stock options from Genentech, Inc., a member of the Roche Group. Thomas Kuenzel and Miriam Triyatni report employment by and stock/stock options from F. Hoffmann-La Roche Ltd. Hiroaki Ida reports employment by and stock/stock options from Chugai Pharmaceutical Co., Ltd.
: The trials adhered to the ethical guidelines set out in the Declaration of Helsinki and by the Council for International Organizations of Medical Sciences and complied with the International Council for Harmonisation E6 guideline for Good Clinical Practice and applicable laws and regulations. IRB approval was received for this study protocol, please see the supplementary material for a full list. Written informed consent was obtained before participants enrolled in these trials.
